Literature DB >> 34287725

First case of hemicrania continua responsive to galcanezumab.

Vicente González-Quintanilla1, Sara Pérez-Pereda1, Noelia Fontanillas2, Julio Pascual3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34287725     DOI： 10.1007/s10072-021-05476-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  2 in total

1.  Trial of Galcanezumab in Prevention of Episodic Cluster Headache.

Authors:  Peter J Goadsby; David W Dodick; Massimo Leone; Jennifer N Bardos; Tina M Oakes; Brian A Millen; Chunmei Zhou; Sherie A Dowsett; Sheena K Aurora; Andrew H Ahn; Jyun-Yan Yang; Robert R Conley; James M Martinez
Journal:  N Engl J Med       Date:  2019-07-11       Impact factor: 91.245

2.  Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.

Authors:  Jennifer Robblee; Katrina L Devick; Natasha Mendez; Jamie Potter; Jennifer Slonaker; Amaal J Starling
Journal:  Headache       Date:  2020-09-13       Impact factor: 5.887
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.